PDF herunterladen
Thromb Haemost 1987; 58(04): 1043-1048
DOI: 10.1055/s-0038-1646053
Original Article
Schattauer GmbH Stuttgart

F VIII Subunits: Purification and Antigenic Properties

Ole Nordfang
Nordisk Gentofte AIS, Gentofte, Denmark
,
Mirella Ezban
Nordisk Gentofte AIS, Gentofte, Denmark
,
Jan J Hansen
Nordisk Gentofte AIS, Gentofte, Denmark
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 09. April 1987

Accepted after revision 24. August 1987

Publikationsdatum:
29. Juni 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Factor VIII-Light Chain (FVIII-LC) and FVIII-Heavy Chain (FVIII-HC) were purified from human plasma by the use of immunosorbents containing monoclonal antibodies or human inhibitor antibodies. FVIII-LC was subsequently isolated in essentially pure state by cation exchange chromatography. The preparations obtained contained 50 ng of protein for each unit of FVIII-LC antigen (FVIII-LC: Ag).

Affinity purified FVIII-LC and FVIII-HC preparations containing less than 0.3% of the opposite subunit were added in FVIILC inhibition assay of hemophilia A inhibitor antibodies. FVIII-LC was able to fully block the inhibitor activity in 6 out of 7 hemophilia A plasmas and partially block the inhibitor activity of one plasma. FVIII-HC only blocked FVIILC inhibiting antibodies form the plasma that was not fully blocked by FVIII-LC. It is suggested that FVIII-LC can be used for immunotherapy of the patients whose FVIILC inhibiting antibodies are directed towards FVIII-LC.

When FVIII-LC was coupled to Sepharose at a concentration of 4800 units of FVIII-LC: Ag per ml Sepharose, 0.2 ml of the immunosorbent was able to bind 900 Bethesda units from 100 ml hemophilia A inhibitor plasma. This opens the possibility to remove FVIII inhibitor antibodies from circulation by extracorporeal immunotherapy with FVIII-LC coupled to Sepharose.

Keywords

Factor VIII - Hemophilia A inhibitor antibodies - Factor VIII Light Chain - Factor VIII Heavy Chain
 

  • References

  • 1 Hultin MB. Role of human factor VIII in factor X activation. J Clin Invest 1982; 69: 950-958
    CrossrefPubMedGoogle Scholar
  • 2 Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-29
    PubMedGoogle Scholar
  • 3 Lazarchick J, Hoyer LW. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-1052
    CrossrefPubMedGoogle Scholar
  • 4 Ljung R, Holmberg L. FVIII-CAg in haemophilia A. A comparison between IRMA’s using haemophilic and spontaneous antibodies. Thromb Res 1981; 24: 45-50
    CrossrefPubMedGoogle Scholar
  • 5 Gitschier J, Wood WI, Goralka M, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330
    CrossrefPubMedGoogle Scholar
  • 6 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham E GD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337
    CrossrefPubMedGoogle Scholar
  • 7 Vehar GA, Keyt B, Eaton D, Rodriques H, O’Brian DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham E GD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342
    CrossrefPubMedGoogle Scholar
  • 8 Toole JJ, Knopf JL, Woznev JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Schoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
    CrossrefPubMedGoogle Scholar
  • 9 Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP, Najarian R, Pachl C, Potler SJ, Puma J, Quiroga M, Rail LB, Randolph A, Urdea MS, Valenzuela P, Dahl HH, Favaloro J, Hansen J, Nordfang O, Ezban M. Characterization of the polypeptide composition of human factor VIII :C and the nucleotide sequence and expression of the human kidney. cDNA DNA 1985; 4: 333-349
    PubMedGoogle Scholar
  • 10 Hoyer LW. The factor VIII complex: Structure and function. Prog Clin Biol Res 1981; 72: 1-26
    PubMedGoogle Scholar
  • 11 Wion KL, Kelly D, Summerfield JA, Tuddenham E GD, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-729
    CrossrefPubMedGoogle Scholar
  • 12 Rail LB, Bell GI, Caput D, Truett MA, Masiarz FR, Najarian RC, Valenzuela P, Andersen HD, Din N, Hansen B. Factor VIII :C synthesis in the kidney. Lancet 1985; ii: 44
    PubMedGoogle Scholar
  • 13 Fulcher CA, Zimmerman T. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-1652
    CrossrefPubMedGoogle Scholar
  • 14 Eaton D, Rodriquez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512
    CrossrefPubMedGoogle Scholar
  • 15 Andersson LO, Forsman N, Huang K, bLarsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate and plasma. Proc Natl Acad Sci USA 1986; 83: 2979-2983
    CrossrefPubMedGoogle Scholar
  • 16 Burke RL, Pachl C, Quiroga M, Rosenberg S, Haigwood N, Nordfang O, Ezban M. The functional domains of coagulation factor VIII :C. J Biol Chem 1986; 261: 12574-12578
    PubMedGoogle Scholar
  • 17 Nordfang O, Ezban M, Dinesen B. Reactivity of factor VIII inhibitors in a micro ELISA for factor VIII: CAg and in solid phase immunoiso-lation of VIII: CAg. Thromb Haemostas 1985; 53: 346-350
    PubMedGoogle Scholar
  • 18 Marder VJ, Mannucci PM, Firkin BG, Hoyer LW, Meyer D. Standard nomenclature for factor VIII and von Willebrand factor: A recoinendalioii by the in lei national committee on Lhiombosis and haemostasis. Thromb Haemostas 1985; 54: 871-872
    PubMedGoogle Scholar
  • 19 Nordfang O, Ezban M, Hansen JJ. Specificity of factor VIII inhibitor antibodies and purification of factor VIII: C antigen. Factor VUI/von Willebrand Factor. Wichtig Editore; Milan: 1986. pp 243-252
    Google Scholar
  • 20 Fulcher CA, Mahoney SG, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-7732
    CrossrefPubMedGoogle Scholar
  • 21 Fulcher CA, Mahoney S, Roberts JR, Zimmerman TS. Immunoblot-ting studies of factor VIII inhibitor epitope specificity and subclass. Res Clin lab 1986; 16: 112 (Abstr)
    PubMedGoogle Scholar
  • 22 Newman J, Johnson AJ, Karpatkin MH. Puszkins Methods for the production of clinically effective intermediate and high-purity F Vlll-concentrates. Brit J Haematol 1971; 21: 1-20
    CrossrefPubMedGoogle Scholar
  • 23 Nordfang O, Ezban M, Favaloro JM, Dahl H HM, Hansen JJ. Specificity of monoclonal antibodies to factor VIII :C. Thromb Haemostas 1985; 54: 586-590
    PubMedGoogle Scholar
  • 24 Proctor RD, Rapaport SI. The partial thromboplastin time with Kaolin. Am J Clin Pathol 1961; 36: 212-219
    CrossrefPubMedGoogle Scholar
  • 25 Kasper CK, Aledort LM, Courts RB, Edson JR, Fratanti IJ, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Paol JG, Shapiro SS, Shalman NR, van Eys J. A more uniforn measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 869-872
    PubMedGoogle Scholar
  • 26 Rosen S. Assay for factor FVIII:C with a chromogenic substrate. Scand J Haematol 1984; 33 suppl. (40) 139-145
    PubMedGoogle Scholar
  • 27 Prowse C, Hornsey V, McKay G, Waterson Y. Room temperature, microtray chromogenic assay of Factor VIII :C. Vox Sang 1986; 50: 21-25
    CrossrefPubMedGoogle Scholar
  • 28 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 29 Morrissey JH. Silver stain for proteins in polyacrylamide gels: A modified procedure with enhanced uniform sensitivity. Anal Biochem 1981; 117: 307-310
    CrossrefPubMedGoogle Scholar
  • 30 Fass DN, Knutson GJ, Katzman J. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982; 59: 594-600
    PubMedGoogle Scholar
  • 31 Fulcher CA, Roberts JR, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: Correlation of activation with generation of specific polypeptides. Blood 1983; 61: 807-811
    PubMedGoogle Scholar
  • 32 Nilsson IM, Sundquist SB, Freiburghaus C. Extracorporeal protein A-Sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984; 150: 225-241
    PubMedGoogle Scholar
  • 33 Tuddenham E GD, O’Brien DP. Factor VIII: epitope mapping and interaction with thrombin. Factor Vlll/von Willebrand Factor. Wichtig Editore; Milan: 1986. pp 217-223
    Google Scholar
  • 34 Hoyer LW. The factor VIII complex: Structure and function. Blood 1981; 58: 1-13
    PubMedGoogle Scholar
  • 35 Chavin SI. Factor VIII: Structure and function in blood clotting. Am J Hematol 1984; 16: 297-306
    CrossrefPubMedGoogle Scholar
  • 36 Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-195
    PubMedGoogle Scholar
  • 37 Stenbjerg S, Ingerslev J, Zackariae E. Factor VIII inhibitor treatment with high doses of FVIII. Thromb Res 1984; 34: 533-539
    CrossrefPubMedGoogle Scholar
  • 38 Scheibel E, Feddersen C, Hertz H. Long-term high dose factor VIII treatment of 3 haemophiliacs with factor VIII inhibitor. Scand J Haematol 1985; 34: 378-384
    PubMedGoogle Scholar
  • 39 Hasek M, Hraba T. Active mechanisms of immunological tolerance. Surv Immunol Res 1984; 3: 253-259
    PubMedGoogle Scholar